Back to search

Article

A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)

2024-10-11

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold> Dexamethasone is an antiemetic drug widely used to prevent nausea and vomiting caused by anticancer drugs. However, dexamethasone can cause several side effects even after short-term administration. Therefore, the development of dexamethasone-free antiemetic therapies has been recognized as an important challenge. The objective of this study was to investigate the e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2c2d54fa-5bfe-598b-aa10-76c088032e74
DOI
10.21203/rs.3.rs-4832452/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)DOI 10.21203/rs.3.rs-4832452/v1
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: A systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologySemantic proximity
5-Hydroxytryptamine-3 Receptor Antagonist and Dexamethasone as Prophylaxis for Chemotherapy Induced Nausea and Vomiting during Moderately Emetic Chemotherapy for Solid Tumors: A Multicenter, Prospective, Observational StudySemantic proximity
Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapySemantic proximity
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.Semantic proximity
Personalized prophylactic antiemetic regimens for the control of chemotherapy-induced nausea and vomiting by pharmacogenetic analysis of three receptors genes:<i>HTR3A, HTR3B, TACR1</i>Semantic proximity
Successful Dexamethasone Dose Reduction During Weekly Paclitaxel/Carboplatin with Chemoradiotherapy: Two Delirium-Associated CasesSemantic proximity
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Semantic proximity
Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational StudySemantic proximity
Delayed chemotherapy-induced nausea – Occurrence and corelates in an international multi-center study in adult oncology patients in clinical practice (CINrate)Semantic proximity
A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancerSemantic proximity
Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Se-Quencing, and SafetySemantic proximity
Efficacy and Safety of Bevacizumab-Containing Therapy in Refractory Advanced Breast Cancer：A Retrospective StudySemantic proximity
Select a neighboring publication to make it the new centre.